DIABETIC NEPHROPATHY & CKD PRECLINICAL CRO SERVICES

Physiogenex offers diabetic nephropathy and Chronic Kidney Disease (CKD) preclinical CRO services to evaluate your drugs targeting these pathologies. We use our unique and benchmarked animal models: the db/db mouse on high protein diet and the Unx/salt supplemented SDT fatty rat models.

Both models were awarded at the 16th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in 2018 (see the poster).

Benefit from our experience in measuring the glomerular filtration rate with Medibeacon devices, which enable multiple, sensitive and less invasive measurement of kidney function during drug treatment.

Besides tracking plasma and urine parameters, our clients benefit from our complete histology services panel and histopathology scoring to fully characterize kidney lesions.

Our experience in animal models of diabetic nephropathy and our expertise as consultancy services will optimize and accelerate your drug development program for diabetic nephropathy.

Major publications on diabetic nephropathy

• Briand F, Norgaard S, Shinohara M, Brousseau E, Faresse N, Ohta T, Kageyama Y, Sand F, Sulpide T. “SGLT2 inhibitor dapaglifozin reduces hyperfiltration and prevents glomerular filtration rate decline in rodent models of diabetic nephropathy”. Physiogenex; GLP-1 & T2D Pharmacology, Novo Nordisk A/S; CLEA Japan Inc., Tokyo, Japan; Japan Tobacco Inc., Osaka, Japan. (2019) 16 ANNUAL WORLD CONGRESS ON INSULIN RESISTANCE, DIABETES & CARDIOVASCULAR DISEASE (WCIRDC). Endocrine Practice: January 2019, Vol. 25, No. 1, pp. 1A-43A.